BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37161535)

  • 1. CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma.
    Wenger A; Karlsson I; Kling T; Carén H
    Clin Epigenetics; 2023 May; 15(1):80. PubMed ID: 37161535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
    Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
    Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster.
    Berlandi J; Chaouch A; De Jay N; Tegeder I; Thiel K; Shirinian M; Kleinman CL; Jeibmann A; Lasko P; Jabado N; Hasselblatt M
    Neuro Oncol; 2019 May; 21(5):628-639. PubMed ID: 30715493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.
    Ross JL; Chen Z; Herting CJ; Grabovska Y; Szulzewsky F; Puigdelloses M; Monterroza L; Switchenko J; Wadhwani NR; Cimino PJ; Mackay A; Jones C; Read RD; MacDonald TJ; Schniederjan M; Becher OJ; Hambardzumyan D
    Brain; 2021 Feb; 144(1):53-69. PubMed ID: 33300045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
    Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
    Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
    Kasper LH; Baker SJ
    Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone H3K27M Mutation in Brain Tumors.
    El-Hashash AHK
    Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
    Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
    Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
    Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
    Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
    Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D'Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA
    Sci Rep; 2023 Mar; 13(1):3775. PubMed ID: 36882456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
    Tan JY; Wijesinghe IVS; Alfarizal Kamarudin MN; Parhar I
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
    Day CA; Hinchcliffe EH; Robinson JP
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
    Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
    Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma.
    Carvalho D; Mackay A; Bjerke L; Grundy RG; Lopes C; Reis RM; Jones C
    Acta Neuropathol Commun; 2014 Feb; 2():23. PubMed ID: 24548782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
    Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncohistone interactome profiling uncovers contrasting oncogenic mechanisms and identifies potential therapeutic targets in high grade glioma.
    Siddaway R; Canty L; Pajovic S; Milos S; Coyaud E; Sbergio SG; Vadivel Anguraj AK; Lubanszky E; Yun HY; Portante A; Carette S; Zhang C; Moran MF; Raught B; Campos EI; Hawkins C
    Acta Neuropathol; 2022 Nov; 144(5):1027-1048. PubMed ID: 36070144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.